Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 4Terminated 3Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1

Conditions

Breast Neoplasms 2Malignant Solid Neoplasm 1Inflammatory Breast Neoplasms 1

Interventions

pembrolizumab 85Specimen Handling 79Carboplatin 73Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 54Paclitaxel 46Cyclophosphamide 44durvalumab 37Radiotherapy 36Radiation 35olaparib 34Rituximab 34Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Taxes 27Doxorubicin 27Docetaxel 27Pemetrexed 26Bevacizumab 24Prednisone 23Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Has results × 2C4 antibody × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
18 enrolled 8 charts
Breast

Breast Neoplasms

NCT01730833 2025-06-03

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
63 enrolled 11 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡